STOCK TITAN
  1. Home
  2. News
  3. DGX

Quest Diagnostics Inc. - DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Quest Diagnostics Inc. (NYSE: DGX) is a leading provider of diagnostic testing, information, and services in the United States, enabling people to make informed health decisions. The company provides diagnostic insights derived from the world’s largest database of clinical lab results, which aids in identifying and treating diseases, promoting healthy behaviors, and improving healthcare management.

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce of nearly 50,000 employees is dedicated to transforming lives by providing actionable diagnostic insights. The company offers the broadest test menu available, with over 3,000 different tests, and has a strong focus on cancer diagnostics, anatomic pathology, and interpretive consultations through its medical and scientific staff of approximately 900 M.D.s and Ph.D.s.

In recent years, Quest Diagnostics has been at the forefront of innovation in diagnostic testing. The company has significantly invested in AI and digital pathology to enhance the accuracy and efficiency of cancer diagnoses. A notable collaboration with PathAI aims to accelerate the adoption of digital and AI pathology technologies, thereby improving the quality, speed, and efficiency of diagnosing cancer and other diseases. This partnership includes the acquisition of PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee, which will serve as Quest’s AI and digital R&D and solutions center.

Financially, Quest Diagnostics has shown robust performance, with annual revenues reaching $7.4 billion in 2014. The company continues to strengthen its market presence through strategic acquisitions and partnerships, expanding its services and enhancing its capabilities in specialized pathology services. The integration of digital and AI technologies across its operations has improved quality, efficiency, and customer satisfaction, positioning Quest Diagnostics as a leader in the diagnostic services industry.

Quest Diagnostics' extensive clinical testing network includes roughly 2,300 patient service centers, numerous doctors' offices, and hospitals nationwide. The company also provides clinical trials testing, risk assessment services, and information technology solutions through its diagnostic solutions segment.

By leveraging its comprehensive diagnostic insights, Quest Diagnostics aims to empower individuals and healthcare providers to make informed decisions that lead to better health outcomes, ultimately contributing to a healthier world.

News

Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"

Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) has been recognized as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year. The company scored high marks in people management, use of corporate assets, and social responsibility, making it one of only five companies to attain Most Admired status in the 'Health Care: Pharmacy and Other Services' industry. The recognition is based on nine criteria of corporate reputation, including innovation, quality of management and products, and social responsibility. Quest Diagnostics' Chairman, CEO, and President, Jim Davis, expressed gratitude to the company's dedicated colleagues for their role in achieving this honor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News

Fitbit and Quest Diagnostics Collaborate To Advance Research on the Use of Wearable Devices To Improve Metabolic Health

Rhea-AI Summary
Fitbit and Quest Diagnostics (NYSE:DGX) have announced a collaboration to study the potential of wearable devices to improve metabolic health, aiming to evaluate the effect of wearables on users' behaviors based on objective laboratory test results. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair behavioral and biometric data from Fitbit devices with health insights from Quest Diagnostics' laboratory tests to explore ways data can be combined and analyzed to improve the assessment and management of metabolic health and help to inform the prevention of disease. The study will invite approximately 1,500 existing Fitbit users to join and consent to share three months of their Fitbit data and receive laboratory testing at no cost using a panel of blood tests specifically designed to assess metabolic health. This study is expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
News

Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma

Rhea-AI Summary
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. The collaboration aims to overcome challenges associated with treating liver and pancreatic tumors by utilizing Haystack MRD™ technology to accurately detect circulating tumor DNA (ctDNA) with unparalleled sensitivity in patients with low tumor burden and in clinically challenging cancer types. The partnership is focused on supporting the clinical development of SD-101 in combination with TriSalus' unique therapy delivery technology, Pressure-Enabled Drug Delivery™ (PEDD™). This collaboration has the potential to offer better therapeutic options for patients with liver and pancreatic tumors, addressing significant challenges in the development of immunotherapies for these cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
clinical trial
News

Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024

Rhea-AI Summary
Quest Diagnostics (DGX) will report Q4 and full year 2023 financial results on February 1, 2024. The company will hold a conference call to discuss the results and provide access to a live webcast. Participants can access the call and webcast via dial-in or online replay. The company encourages participants to read its periodic reports on file with the SEC, including risk factors and historical results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
earnings
-
News

Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

Rhea-AI Summary
Fitbit and Quest Diagnostics (NYSE: DGX) have announced a collaboration to study the potential of wearable devices to improve metabolic health, aiming to assess and manage metabolic health to prevent diseases like diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair behavioral and biometric data from Fitbit devices with health insights from Quest Diagnostics' laboratory tests to explore ways data can be combined and analyzed to improve health outcomes. The study will invite 1,500 Fitbit users to join and consent to share three months of their Fitbit data, as well as receive laboratory testing at no cost using a panel of blood tests specifically designed to assess metabolic health. The study is expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
News

Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing

Rhea-AI Summary
Ultima Genomics (UG) and Quest Diagnostics (DGX) collaborate to improve patient access, affordability, and outcomes through the use of Ultima's next generation sequencing (NGS) technology in oncology and other clinical areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
News

Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System

Rhea-AI Summary
Quest Diagnostics (DGX) acquires select assets of Steward Health Care System's outreach laboratory services business in Pennsylvania and Ohio to broaden access to innovative, quality, and cost-effective laboratory services. The financial details of the transaction were not disclosed. The acquisition aims to serve the evolving needs of health systems and aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
acquisition
-
News

Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC

Rhea-AI Summary
Haystack Oncology (DGX) collaborates with Alliance Foundation Trials, LLC (AFT) to utilize its personalized MRD technology (Haystack MRD™) in AFT-57 clinical trial for unresectable stage III non-small cell lung cancer. The study, supported by Genentech, will evaluate the efficacy and safety of atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
clinical trial
-
News

No-Cost Testing Helps Bolster I-HEAL Community Wellness Day in Mississippi Delta Region

Rhea-AI Summary
Quest Diagnostics (ticker symbol: QD) provided no-cost Blueprint for Wellness® testing to over 100 local community members at the ninth annual I-HEAL Community Wellness Day in the Mississippi Delta region. The event, hosted by Quest for Health Equity (Q4HE) grantee Glenn Family Foundation, offered health screenings, nutritious food, mental health resources, vaccines, cleaning supplies, and diapers. Blueprint for Wellness offers comprehensive health screenings to empower individuals with personalized health insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
News

Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Quest Diagnostics Incorporated (NYSE: DGX) to Present at J.P. Morgan Healthcare Conference, Offering Insight into Company Strategy and Market Trends
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences

FAQ

What is the current stock price of Quest Diagnostics (DGX)?

The current stock price of Quest Diagnostics (DGX) is $160.44 as of November 15, 2024.

What is the market cap of Quest Diagnostics (DGX)?

The market cap of Quest Diagnostics (DGX) is approximately 18.0B.

What does Quest Diagnostics do?

Quest Diagnostics provides diagnostic testing, information, and services that help healthcare providers and patients make informed health decisions. The company offers a broad range of tests and diagnostic insights derived from the world’s largest database of clinical lab results.

How many people does Quest Diagnostics serve annually?

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States each year.

What are some recent achievements of Quest Diagnostics?

Recently, Quest Diagnostics has partnered with PathAI to enhance its AI and digital pathology capabilities. The acquisition of PathAI Diagnostics' digital laboratory will serve as a new AI and digital R&D center, improving cancer diagnosis quality and efficiency.

What kind of tests does Quest Diagnostics offer?

Quest Diagnostics offers over 3,000 different tests, including clinical testing, anatomic pathology, esoteric testing, and substance abuse testing.

What is the company's approach to innovation?

Quest Diagnostics focuses on incorporating AI and digital technologies into its diagnostic services to enhance accuracy, efficiency, and accessibility of its offerings. The company also pilots new technologies and expands its capabilities through strategic partnerships and acquisitions.

How extensive is Quest Diagnostics' clinical testing network?

Quest Diagnostics operates an extensive clinical testing network with approximately 2,300 patient service centers, as well as numerous doctor’s offices and hospitals across the United States.

What role do partnerships play at Quest Diagnostics?

Partnerships, such as the recent collaboration with PathAI, play a crucial role in Quest Diagnostics' strategy to integrate advanced technologies and expand its capabilities in specialized diagnostic services.

How does Quest Diagnostics contribute to healthcare management?

Quest Diagnostics provides diagnostic insights that help identify and treat diseases, inspire healthy behaviors, and improve healthcare management. These insights support more informed decision-making by both patients and healthcare providers.

What are the company’s future plans?

Quest Diagnostics plans to continue expanding its capabilities in AI and digital pathology, enhance its clinical testing services, and maintain its leadership in diagnostic information services. The company aims to leverage its diagnostic insights to empower better healthcare outcomes globally.

How does Quest Diagnostics ensure the quality of its services?

Quest Diagnostics employs nearly 50,000 dedicated professionals, including about 900 M.D.s and Ph.D.s, and integrates cutting-edge technology and rigorous quality control measures across its operations to ensure high-quality diagnostic services.

Stock DGX logo
Quest Diagnostics Inc.

NYSE:DGX

DGX Rankings

#592 Ranked by Market Cap
#1433 Ranked by Dividends

DGX Stock Data

18.01B
111.62M
0.43%
90.98%
2.08%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SECAUCUS